#USA #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense and EverythingALS Event Overview

On June 24, 2026, EverythingALS will host an essential community event, dubbed PrimeC - Connecting the Dots, in collaboration with NeuroSense Therapeutics Ltd. This initiative seeks to unpack the promising findings related to NeuroSense's lead product, PrimeC, which has shown potential in treating amyotrophic lateral sclerosis (ALS).

Event Details

The event is scheduled to take place at 7 PM ET and is geared towards individuals living with ALS, their families, and caregivers, as well as clinicians interested in the latest advancements in ALS treatment options. Attendees are encouraged to register online, ensuring they can engage deeply with discussions that matter most to the ALS community.

Featured Speaker

At the event, participants will hear from distinguished speakers, including Professor Jeffrey Rosenfeld, MD, PhD, FAAN, known for his expertise in neurology and extensive experience caring for ALS patients. With over three decades of experience in multidisciplinary ALS programs, Prof. Rosenfeld will present insights drawn from the latest clinical data regarding PrimeC.

Alongside him will be Alon Ben-Noon, Co-Founder and CEO of NeuroSense Therapeutics, who will join the conversation to elucidate the significance of PrimeC’s findings.

What is PrimeC?

PrimeC is a groundbreaking oral medication developed to target multiple neurobiological pathways implicated in ALS and Alzheimer's disease (AD). This novel therapy combines two marketed drugs, ciprofloxacin and celecoxib, in an innovative fixed-dose combination designed to mitigate neuron degeneration, inflammation, and other cellular stress factors.

In clinical trials, particularly in the Phase 2b PARADIGM study, PrimeC demonstrated encouraging results, showcasing the ability to slow disease progression in ALS patients. Notably, follow-up data revealed a potential survival benefit for patients, raising hopes for a substantial advancement in ALS treatment paradigms.

Importance of Community Engagement

The event aims to foster a supportive space for educational exchange, encouraging dialogue between ALS patients, their caregivers, and the scientific community. By sharing insights about the latest developments in ALS research, EverythingALS and NeuroSense aspire to empower individuals affected by ALS and enhance their understanding of treatment options.

This event highlights NeuroSense’s commitment to transparency and community collaboration. By engaging directly with the ALS community, NeuroSense demonstrates its dedication to developing treatments that can significantly improve the quality of life for individuals battling this neurodegenerative disease.

Conclusion

The PrimeC event hosted by EverythingALS promises to be a pivotal moment for the ALS community. As the field of neurodegenerative disease research continues to evolve, opportunities like this will be crucial in bridging gaps between emerging science and real-world applications for patients and families. Registration is open now, and individuals interested in ALS advancements are encouraged to join this vital conversation.

For more details and to register for the event, visit the NeuroSense Therapeutics website or social media channels for updates on the latest in ALS research.